Skip to main content
SpringerLink
Log in

Distinct spatiotemporal patterns for disease duration and stage in Parkinson’s disease

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

To assess correlations between the degree of dopaminergic depletion measured using single-photon emission computed tomography (SPECT) and different clinical parameters of disease progression in Parkinson’s disease (PD).

Methods

This retrospective study included 970 consecutive patients undergoing 123I-ioflupane SPECT scans in our institution between 2003 and 2013, from which we selected a study population of 411 patients according to their clinical diagnosis: 301 patients with PD (69.4 ± 11.0 years, of age, 163 men) and 110 patients with nondegenerative conditions included as controls (72.7 ± 8.0 years of age, 55 men). Comprehensive and operator-independent data analysis included spatial normalization into standard space, estimation of the mean uptake values in the striatum (caudate nucleus + putamen) and voxel-wise correlation between SPECT signal intensity and disease stage as well as disease duration in order to investigate the spatiotemporal pattern of the dopaminergic nigrostriatal degeneration. To compensate for potential interactions between disease stage and disease duration, one parameter was used as nonexplanatory coregressor for the other.

Results

Increasing disease stage was associated with an exponential decrease in 123I-ioflupane uptake (R 2 = 0.1501) particularly in the head of the ipsilateral caudate nucleus (p < 0.0001), whereas increasing disease duration was associated with a linear decrease in 123I-ioflupane uptake (p < 0.0001; R 2 = 0.1532) particularly in the contralateral anterior putamen (p < 0.0001).

Conclusion

We observed two distinct spatiotemporal patterns of posterior to anterior dopaminergic depletion associated with disease stage and disease duration in patients with PD. The developed operator-independent reference database of 411 123I-ioflupane SPECT scans can be used for clinical and research applications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Italian Neurological Society, Italian Society of Clinical Neurophysiology. Guidelines for the Treatment of Parkinson’s Disease. The diagnosis of Parkinson’s disease. Neurol Sci. 2003;24(3 Suppl):S157–64.

    Google Scholar 

  2. Scherfler C, Seppi K, Donnemiller E, Goebel G, Brenneis C, Virgolini I, et al. Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson’s disease. Brain. 2005;128:1605–12.

    Article  PubMed  Google Scholar 

  3. Brücke PD, Asenbaum S, Pirker W, Djamshidian S, Wenger S, Wöber C, et al. Measurement of the dopaminergic degeneration in Parkinson’s disease with [123I]β-CIT and SPECT. J Neural Transm Suppl. 1997;50:9–24.

    Article  PubMed  Google Scholar 

  4. Sixel-Döring F, Liepe K, Mollenhauer B, Trautmann E, Trenkwalder C. The role of 123I-FP-CIT-SPECT in the differential diagnosis of Parkinson and tremor syndromes: a critical assessment of 125 cases. J Neurol. 2011;258:2147–54.

    Article  PubMed  Google Scholar 

  5. Kägi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatr. 2010;81:5–12.

    Article  PubMed  Google Scholar 

  6. Segovia F, Górriz JM, Ramirez J, Alvarez I, Jimenez-Hoyuela JM, Ortega SJ. Improved parkinsonism diagnosis using a partial least squares based approach. Med Phys. 2012;39:4395–403.

    Article  PubMed  CAS  Google Scholar 

  7. Tissingh G, Bergmans P, Booij J, Winogrodzka A, van Royen EA, Stoof JC, et al. Drug-naive patients with Parkinson’s disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]β-CIT SPECT. J Neurol. 1997;245:14–20.

    Article  Google Scholar 

  8. Laruelle M, Wallace E, Seibyl JP, Baldwin RM, Zea Ponce Y, Zoghbi SS, et al. Graphical, kinetic, and equilibrium analyses of in vivo [123I] beta-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab. 1994;14:982–94.

    Article  PubMed  CAS  Google Scholar 

  9. Benamer HT, Patterson J, Wyper DJ, Hadley DM, Macphee GJ, Grosset DG. Correlation of Parkinson’s disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord. 2000;15:692–8.

    Article  PubMed  CAS  Google Scholar 

  10. Marek K, Innis R, van Dyck C, Fussell B, Early M, Eberly S, et al. [123I]β-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression. Neurology. 2001;57:2089–94.

    Article  PubMed  CAS  Google Scholar 

  11. Djaldetti R, Treves TA, Ziv I, Melamed E, Lampl Y, Lorberboym M. Use of a single [123I]-FP-CIT SPECT to predict the severity of clinical symptoms of Parkinson disease. Neurol Sci. 2009;30:301–5.

    Article  PubMed  Google Scholar 

  12. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427–42.

    Article  PubMed  CAS  Google Scholar 

  13. Garibotto V, Montandon ML, Viaud CT, Allaoua M, Assal F, Burkhard PR, et al. Regions of interest-based discriminant analysis of DaTSCAN SPECT and FDG-PET for the classification of dementia. Clin Nucl Med. 2013;38:e112–7.

    Article  PubMed  Google Scholar 

  14. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am J Roentgenol. 1987;149:351–6.

    Article  PubMed  CAS  Google Scholar 

  15. Jenkinson M, Smith S. A global optimisation method for robust affine registration of brain images. Med Image Anal. 2001;5:143–56.

    Article  PubMed  CAS  Google Scholar 

  16. Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage. 2002;17:825–41.

    Article  PubMed  Google Scholar 

  17. García-Gómez FJ, García-Solís D, Luis-Simón FJ, Marín-Oyaga VA, Carrillo F, Mir P, et al. Elaboration of the SPM template for the standardization of SPECT images with 123I-Ioflupane. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2013;32:350–6.

    Google Scholar 

  18. Kas A, Payoux P, Habert M-O, Malek Z, Cointepas Y, El Fakhri G, et al. Validation of a standardized normalization template for statistical parametric mapping analysis of 123I-FP-CIT images. J Nucl Med. 2007;48:1459–67.

    Article  PubMed  Google Scholar 

  19. Smith SM, Nichols TE. Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage. 2009;44:83–98.

    Article  PubMed  Google Scholar 

  20. Morrish PK, Sawle GV, Brooks DJ. An [F-18]dopa-PET and clinical study of the rate of progression in Parkinson’s disease. Brain. 1996;119:585–91.

    Article  PubMed  Google Scholar 

  21. Seibyl JP, Marchek KL, Quinlan D, Sheff K, Zoghbi S, Zea Ponce Y, et al. Decreased single‐photon emission computed tomographic {123I}β‐CIT striatal uptake correlates with symptom severity in Parkinson’s disease. Ann Neurol. 1995;38:589–98.

    Article  PubMed  CAS  Google Scholar 

  22. Ishikawa T, Dhawan V, Kazumata K, Chaly T, Mandel F, Neumeyer J, et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med. 1996;37:1760–5.

    PubMed  CAS  Google Scholar 

  23. Booij J, Tissingh G, Winogrodzka A, Boer GJ, Stoof JC, Wolters EC, et al. Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson’s disease. Eur J Nucl Med. 1997;24:68–71.

    Article  PubMed  CAS  Google Scholar 

  24. Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen A, van Royen EA, et al. Iodine-123-N-omega-fluoropropyl-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson’s disease. J Nucl Med. 1998;39:1143–8.

    PubMed  CAS  Google Scholar 

  25. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson’s disease. Pathophysiologic and clinical implications. N Engl J Med. 1988;318:876–80.

    Article  PubMed  CAS  Google Scholar 

  26. Seibyl JP, Marek KL, Quinlan D, Sheff K, Zoghbi S. Decreased SPECT [123I]beta-CIT striatal uptake correlates with symptom severity in idiopathic Parkinson’s disease. Ann Neurol. 1995;38:589–98.

    Article  PubMed  CAS  Google Scholar 

  27. Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease. Brain. 2013;136:2419–31.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain. 1991;114(Pt 5):2283–301.

    Article  PubMed  Google Scholar 

  29. van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Zoghbi SS, Baldwin RM, et al. Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry. 2002;10:36–43.

    Article  PubMed  Google Scholar 

  30. Lavalaye J, Booij J, Reneman L, Habraken JB, van Royen EA. Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers. Eur J Nucl Med. 2000;27:867–9.

    Article  PubMed  CAS  Google Scholar 

  31. Martinez-Martin P, Gil-Nagel A, Gracia LM, Gómez JB, Martínez-Sarriés J, Bermejo F. Unified Parkinson’s disease rating scale characteristics and structure. The Cooperative Multicentric Group. Mov Disord. 1994;9:76–83.

    Article  PubMed  CAS  Google Scholar 

  32. Laruelle M, Baldwin RM, Malison RT, Zea-Ponce Y, Zoghbi SS, al-Tikriti MS, et al. SPECT imaging of dopamine and serotonin transporters with [123I]β-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse. 1993;13:295–309.

    Article  PubMed  CAS  Google Scholar 

  33. Innis RB, Marek KL, Sheff K, Zoghbi S, Castronuovo J, Feigin A, et al. Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]β-CIT. Mov Disord. 1999;14:436–42.

    Article  PubMed  CAS  Google Scholar 

  34. Ahlskog JE, Uitti RJ, O’Connor MK, Maraganore DM, Matsumoto JY, Stark KF, et al. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson’s disease. Mov Disord. 1999;14:940–6.

    Article  PubMed  CAS  Google Scholar 

  35. Varrone A, Dickson JC, Tossici-Bolt L, Sera T, Asenbaum S, Booij J, et al. European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging. 2012;40:213–27.

    Article  PubMed  Google Scholar 

  36. Nobili F, Naseri M, De Carli F, Asenbaum S, Booij J, Darcourt J, et al. Automatic semi-quantification of [123I]FP-CIT SPECT scans in healthy volunteers using BasGan version 2: results from the ENC-DAT database. Eur J Nucl Med Mol Imaging. 2012;40:565–73.

    Article  PubMed  Google Scholar 

Download references

Compliance with ethical standards

ᅟ

Conflicts of interest

None.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent

Informed consent was waived by the local ethics committee (retrospective analysis of imaging data acquired during clinical work-up).

Author information

Authors and Affiliations

  1. Neurology Unit, Department of Clinical Neurosciences, Geneva University Hospitals, Geneva, Switzerland

    Simon Badoud, Nicolas Nicastro & Pierre R. Burkhard

  2. Neurophysiology Unit, Department of Medicine, University of Fribourg (CH), Fribourg, Switzerland

    Simon Badoud

  3. Faculty of Medicine, University of Geneva, Geneva, Switzerland

    Simon Badoud, Nicolas Nicastro, Valentina Garibotto, Pierre R. Burkhard & Sven Haller

  4. Nuclear Medicine and Molecular Imaging Unit, Department of Medical Imaging, Geneva University Hospitals, Geneva, Switzerland

    Valentina Garibotto

  5. Centre de Diagnostique Radiologique de Carouge, Geneva, Switzerland

    Sven Haller

  6. Department of Surgical Sciences, Radiology, Uppsala University, Uppsala, Sweden

    Sven Haller

  7. Department of Neuroradiology, University Hospital Freiburg, Freiburg, Germany

    Sven Haller

Authors
  1. Simon Badoud
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicolas Nicastro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Valentina Garibotto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pierre R. Burkhard
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sven Haller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sven Haller.

Additional information

Keypoints

• Disease stage and disease duration have different spatiotemporal patterns of dopaminergic depletion in PD.

• 123I-Ioflupane uptake in the striatum decreases exponentially with disease stages.

• Disease stage correlates particularly with uptake in the head of the caudate nucleus with ipsilateral predominance.

• 123I-ioflupane uptake in the striatum decreases linearly with disease duration.

• Disease duration correlates particularly with uptake in the anterior putamen with contralateral predominance.

• The operator-independent spatial normalization of 123I-ioflupane SPECT scans provides a reference database for research and clinical studies based on a large sample of 411 patients.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Badoud, S., Nicastro, N., Garibotto, V. et al. Distinct spatiotemporal patterns for disease duration and stage in Parkinson’s disease. Eur J Nucl Med Mol Imaging 43, 509–516 (2016). https://doi.org/10.1007/s00259-015-3176-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-015-3176-5

Keywords

Search

Navigation